Iovance Biotherapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$123M
Industry:Biotech
Founded:N/A
Lead Investor(s):Jefferies LLC

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Iovance Biotherapeutics's estimated annual revenue is currently $13.8M per year.
  • Iovance Biotherapeutics received $172.5M in venture funding in January 2018.
  • Iovance Biotherapeutics's estimated revenue per employee is $63,571
  • Iovance Biotherapeutics's total funding is $123M.

Employee Data

  • Iovance Biotherapeutics has 217 Employees.
  • Iovance Biotherapeutics grew their employee count by 47% last year.
  • Iovance Biotherapeutics currently has 28 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
DiaCarta
$7M4510%N/A-N/A
Geron Corporati...
N/A205N/AN/A-N/A
Rigel Pharmaceu...
$46.8M3024%N/A-N/A
Althea Technolo...
$22.3M144N/AN/A-N/A
INOVA Diagnosti...
$44.3M286N/AN/A-N/A
10X Genomics
$101.2M65346%N/A-N/A
ProTrials Resea...
$33.3M2153%N/A-N/A
Advanced Cell D...
$28.7M1858%N/A-N/A
The J. Craig Ve...
$39.4M254N/AN/A-N/A
CellMax Life
$6.5M4214%N/A-N/A
Missing a competitor? Contribute!?
Submit

Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was initially developed by Dr. Steven A. Rosenberg at the National Cancer Institute (NCI). In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology were reported by NCI to have achieved objective and complete response criteria, respectively. Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. In addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our TIL therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. As we continue advancing our current clinical programs through the introduction of manufacturing and logistical efficiencies aimed at decreasing production time and optimizing distribution processes, we aim to establish TIL therapy as a revolutionary, accessible, mainline cancer therapy.

keywords:N/A

217

Number of Employees

$13.8M

Revenue (est)

28

Current Jobs

47%

Employee Growth %

$123M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Iovance Biotherapeutics News

31-Aug-19 - Iovance Biotherapeutics: Buy the Dip?

The latter opportunity is being pursued most notably by Iovance Biotherapeutics (NASDAQ: IOVA). While promising data from mid-stage and ...

24-Aug-19 - Iovance Biotherapeutics to Present at Upcoming Investor ...

SAN CARLOS, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology ...

31-Aug-19 - CytRx (NASDAQ:CYTR) & Iovance Biotherapeutics (NASDAQ:IOVA) Head to Head Survey

CytRx (NASDAQ:CYTR) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better business? We will ...

Iovance Biotherapeutics Funding

DateAmountRoundLead InvestorsReference
2017-09-21$57.5MUndisclosedJefferies LLCArticle
2018-01-26$143.8MUndisclosedJefferies LLCArticle
2018-01-31$172.5MUndisclosedJefferies LLCArticle

Iovance Biotherapeutics Executive Hires

DateNameTitleReference
2017-08-09Timothy MorrisCFOArticle